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1. Introduction  
1.1 Imaging in drug development  
The development of novel therapeutics follows a typical path from chemical and biological 
activities in the laboratory through extensive clinical testing and if successful, to the 
commercialization of a drug for a given labeled indication. The attrition, the failure of a new 
product to successfully complete all stages of drug testing, is a key metric for defining 
productivity in the pharmaceutical industry. The lack of therapeutic efficacy and poor safety 
profiles are the leading causes of attrition. Several solutions to better address attrition have 
been proposed in order to enhance our knowledge regarding efficacy, safety and 
mechanism of action in pre-clinical and early clinical setups, all in order to minimize late-
stage attrition and make informed decisions regarding the likelihood of the novel 
compounds to successfully complete all stages of drug development and become a product. 
Clinical imaging has the potential to provide key biomarkers and to enable decision-making 
in drug development. Although, imaging is a complementary technology to biofluid-
derived biomarkers, its non-invasive nature provides unique information regarding 
quantitative measurement of function at particular anatomical localization and is highly 
desirable in order to strengthen our confidence in positive clinical outcome.  Imaging, 
therefore, has considerable potential to build upon well-established serum and urine 
biomarkers in order to better validate predictive values of biofluid-derived biomarkers in 
both the pre-clinical and clinical environments. In oncology, imaging techniques are 
complementary to methods that use biomarker techniques to detect presence of tumor 
tissue, tumor progression and response to therapy because imaging modalities provide 
precise anatomical localization of the tumor tissue(s) that generates biomarkers measured in 
fluids. Ultrasonography (US) is one of the emerging technologies that possess several key 
advantages over other molecular imaging modalities.  These include frequency-dependent 
high spatial resolution, real-time imaging, both anatomical and molecular information in the 
single imaging session, freedom from ionizing radiation, inexpensive implementation, 
affordability worldwide, and finally, well-published preclinical and clinical use of US 
technology.  Therefore, research teams can easily access information regarding adequate use 
and predictive value of ultrasound technology to address the specific project needs [1,2].  
1.2 HCC and tumor models  
Hepatocelluar carcinoma (HCC) is the fifth most common cancer and the third cause of cancer-
related death globally that resists conventional chemotherapy and radiotherapy [3-5]. Also, the 
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liver is, in addition to lungs and bones, one of the most common sites of metastases of other 
tumors, in particular colorectal, pancreatic and ovarian cancers. Conventional cytotoxic 
chemotherapy does not significantly prolong survival of patients with primary liver tumors or 
liver metastases, therefore new therapeutic approaches are needed in order to curb the local 
growth of solid tumors as well as micrometastases of HCC.  Given the complexity of the 
interactions between tumor cells and surrounding stroma and uniqueness of 
microvascularization of the liver, there is a strong rationale to combine agents with different 
mechanisms of action when treating HCC, but also to simultaneously target tumor cells and 
surrounding stroma in order to make the tumor microenvironment less friendly (fertile) for 
growth of solid tumors or development of micro-metastases.  In this chapter we describe the 
difference in vascularization between xenograft and orthotopic preclinical models of HCC and 
use of ultrasonogrophy to assess tumor and organ vasculature. Additionally, we emphasize 
the unique value of contrast enhanced ultrasonography to monitor tumor growth and change 
in tumor vasculature over time in order to assess effect of applied therapies.  
1.3 Angiogenesis in tumors   
Angiogenesis is a critical process in local tumor growth and in the invasion and 
development of distant metastases [6,7]. Research investigating molecular pathways of 
tumor angiogenesis has led to the identification of a number of key molecules involved in 
the stimulation of new vessel growth from existing host vasculature. Several of these 
molecules, such as vascular endothelial growth factor and its main receptor 2 (VEGFR2) 
have become targets for antiangiogenic drugs [8,9]. However, successful application of 
novel therapies that target tumor vasculature will require accurate selection of susceptible 
tumors and precise evaluation of early treatment response using adequate preclinical 
models. Previous work has shown that angiogenesis can be successfully characterized in 
vivo by using ultrasonography with microbubble contrast agents bearing anti-integrin 
antibodies adhered to fibroblast growth factor-stimulated vessels [10-12].  
2. Preclinical models of hepatocellular carcinoma  
Preclinical experimentation allows for simultaneous longitudinal implementation of various 
technologies and biomarkers to monitor the tumor take rate, growth and response to treatment 
as well as to confirm and correlate histological and histochemical results at various time points 
with serum or imaging biomarkers, which cannot always be determined in HCC patients. 
2.1 Tumor vasculature in xenograft HCC model 
The vast majority of in vivo oncology studies are performed in xenograft models, 
subcutaneously placed tumor cells in immunodeficient mice or rats. Xenograft models are 
relatively easy to perform since tumor cells are injected in subcutaneous tissue of mice or 
rats and simple caliper measurement of tumor size provides insight regarding tumor take 
rate, growth and the compound efficacy (Figure 1). Since human malignancies never start or 
metastasize to subcutaneous regions of the body, the xenograft models lack many critical 
characteristics of human cancers including lack of preexisting organ vasculature and 
interaction between the tumor cells and cells of the organ where tumor initiated or 
metastasized. Therefore, the main goal of studies using xenograft models is to confirm that 
the “targeted” therapy under investigation hits the intended target that should be present in 
the tumor cell line used in the particular study. In this model there are no pre-existing blood 
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vessels and the newly formed tumor vasculature is fairly simple and consists of nutritional 
arteries designed to provide oxygen and nutrients to the tumor (Figure 1). Consequently, 
antiangiogenic therapy in the HCC xenograft models seems to be very effective against the 
tumor growth [13].  In general, the xenograft models are very informative and allow for 
several types of measurements to be performed simultaneously including caliper 
measurements, IVIS imaging, ultrasonography with and without the contrast agents, PET 
and MRI imaging, measurements of serum or urine biomarkers and finally deployment of 
many histological and histochemical methods. Recently, several groups have demonstrated 
that quantification of intra-tumoral flow of an ultrasound contrast agent with gray-scale 
imaging can be used for monitoring tumor vascular response to anti-angiogenic therapy in 
animal models, a technique that can also be used in the clinic [13-16]. In those studies data 
obtained with ultrasonography paralleled tumor volume data obtained by caliper 
measurement and showed good correlation with tumor histology, allowing assessment of 
necrotic and perfused tumor areas in vivo. 
 
 
Fig. 1. Image of a xenograft of HCC tumor (A), histological appearance of the tumor (B) with 
arrows indicating a blood vessel, and schematic representation of the nutritional blood 
supply to the tumor (C). 
2.2 Tumor vasculature and liver vasculature in orthotopic HCC model 
Orthotopic HCC models of liver tumors are labor-intensive to perform as they require 
surgical inoculation of tumor cells into the liver (or spleen) and the use of sophisticated 
imaging technologies and/or biofluid based biomarkers to monitor the tumor take rate, 
tumor growth and effects of therapy on tumor progression [17]. Because in orthotopic HCC 
models the tumor is placed in the organ of origin, studies performed in those models 
provide more realistic and clinically relevant data regarding compound systemic and tumor 
exposure, efficacy and safety.   
The local vasculature of the liver is extremely complex and is composed of nutritional and 
functional blood supplies that in addition to neo-vasculature created by the tumor itself, 
collectively support tumor growth within the liver (Figure 2). The hepatic artery accounts 
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for only about 65% of the oxygen supply to the liver [18,19]. Slow circulation in the liver and 
an intense nutritional (hepatic artery) and functional (portal vein) vascular network allows 
the tumor to establish, survive and eventually metastasize [20,21]. The blood flow to the 
liver tumor is carried almost exclusively by systemic arterial vessels [22,23]. However, 
oxygen and nutrient supply through the portal vein is respectable, and it has been 
hypothesized that outside edges of the tumor use this alternate route to survive and spread 
to surrounding tissues [24] causing these tumors to be very resistant to antiangiogenic 
therapies. Finally, vascularization in the liver of cancer patients can be further complicated 
by liver cirrhosis [25-27]. Due to technical and other difficulties to reliably describe the exact 
anatomical location of the tumor within the liver, tumor size and growth propensity, 
presence or lack of secondary tumors, as well as tumor response to therapy, scientists that 
utilize orthotopic HCC models in their research as well as clinicians almost entirely depend 
on imaging modalities, including various ultrasound methods.  
 
 
Fig. 2. Overview of a rat liver (A) with orthotopic HCC tumor (arrow head), histological 
appearance of intrahepatic tumor (B) depicting borderline area (arrow) between the tumor 
(T) and normal liver tissue (L) and schematic representation (C) of the nutritional (hepatic 
artery) and functional (portal vein) blood supply in the liver and the intrahepatic tumor, 
emphasizing differences in blood pressure between the two blood systems. 
2.3 Delivery of contrast and/or drug in orthotopic HCC model 
One of the most clinically effective ways to deliver drugs to the liver is through the hepatic 
artery because it allows continuous infusion directly into the arterial bed from which the 
tumor derives nearly all of its blood supply [27,28]. The use of orthotopic animal models 
allows for cannulation of the hepatic artery and portal vein to deliver drugs directly to the 
liver, thus mimicking the clinical arrangement. Due to technical difficulties associated with 
intra-arterial drug delivery, the most common way of dosing animals in preclinical studies is 
via tail-vein injections. Even though tail-vein injections have little similarity with the clinical 
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setup, this method is acceptable as long as the frequency of repeated dosing does not cause 
local tissue damage and necrosis. However, a single bolus injection of a drug or contrast agent 
through the hepatic artery or portal vain is more desirable since it mimics human setup and 
delivers much better results. The differences in the microbubble concentrations in the liver 
following tail-vain, portal vein and hepatic artery delivery are shown in Figures 3.  
 
 
Fig. 3. Ultrasound images of normal rat livers and tumor bearing livers following bolus 
injection of microbubbles (50 µL) into the tail vein, portal vein, or hepatic artery. Take of the 
microbubble contrast (green) by the liver is very high if the injection is made through 
hepatic artery or portal vein, but poor if injection is made through the tail vein. 
Microbubble contrast technology is known to be an extremely useful tool for non-invasive 
assessment of liver vascular structure [29]. Contrast Enhanced Ultrasound Imaging (CEUS) 
is used in both preclinical and clinical studies to diagnose liver tumors and/or liver 
metastases, to monitor disease progression, to deliver drugs and to assess the efficacy of 
antitumor therapies [16,30,31].  
3. Tumor assessment using ultrasound imaging    
Through both structural and functional imaging, ultrasound can provide an integrated suite 
of tools to characterize and monitor tumor changes.  For pre-clinical use, the low-cost and 
real-time capabilities allow for high throughput of analyzed animals. In addition, developed 
imaging biomarkers are often translatable into humans for use in clinical trials. 
3.1 Assessment of tumor volume 
The resolution of an ultrasound B-scan image increases with frequency, though depth 
penetration is diminished due to attenuation. For small-animal imaging, frequencies in the 
range of 20 to 50 MHz can provide sharp images of anatomical structure for depths down to 
1cm.  At 40 MHz, the resolution is on the order of 50 m [32].  In both xenograft and 
orthotopic rodent models, tumors can be viewed with well defined boundaries, allowing for 
quantitative measurement of volume size. 
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Though 3D matrix array probes are slowly becoming more available, accurate volume 
measurements can be obtained with a mechanical sweep of a 2D array. With the tumor bearing 
rodent fixed on a platform, a stepping motor translates the transducer across the region of 
interest. Post-processing of the 2D image sets includes manual outlining of the tumor on 
individual slices to estimate the volume. For small tumors (less than 2 mm3), the coefficient of 
variation for tumor volume measurements has been shown to be on the order of 10% [33]. 
Delineation of tumor boundaries can be further improved with use of the contrast (Figure 4). 
 
 
Fig. 4. Contrast enhanced ultrasound improves tumor identification and measurement.  The 
left image (A) was taken without contrast, and although a shadow is visible (arrow), the 
tumor is difficult to identify.  After contrast administration (B) a tumor mass (arrow) is 
clearly defined and can be readily quantified.   
3.2 Assessment of tumor vascularity using Doppler 
Since angiogenesis is a major enabling factor of tumor growth, the ability to image and 
monitor tumor vascularity is of primary interest in oncology applications of US technology. 
Doppler ultrasound is the standard modality for measuring blood flow. As a transducer 
emits an acoustic pulse, the echoes from moving scatters are shifted in frequency. In brief, 
the pulsed-wave Doppler sends short pulse bursts and gates the return signal 
corresponding to a specific depth. The display of tumor vasculature shows the velocity 
spectrum as a function of time. This technique is most useful for looking at velocity profiles 
of flow in macrovessels such as hepatic veins and arteries (Figure 5).  
Power Doppler, which uses the integrated power of the Doppler signal, does not provide 
directional flow information, but is angle independent and more sensitive to slow flow than 
frequency-shift-based color Doppler. By using the clinical scanners, vessels as small as 100 
m diameter can be clearly visualized. Quantification is typically based on calculating the 
percentage of colorized-pixels in a region of interest. Power Doppler has been shown to 
have a strong correlation (r=0.98) with tumor blood vessels as determined by histological 
staining [34]. Regional variations, rim versus tumor core, can also be evaluated as well as 
heterogeneity of tumor vasculature. 
3.3 Assessment of tumor perfusion using contrast imaging 
Within the past decade, ultrasound contrast agents have been increasingly used to characterize 
vascular dynamics. The current generation of contrast agents is composed of 1-10 m 
sizedmicrobubbles with a perfluorocarbon or hexafluoride gas core surrounded by a lipid 
shell. Injected into the blood stream, microbubbles are stable in the circulatory system for over 10  
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Fig. 5. Example of color Doppler imaging of the normal rat liver.  Color Doppler shows 
directional flow allowing for visualization of the hepatic artery tree and portal vein.  A pulse 
wave Doppler range gate is placed over the colorized vessel to measure flow velocity.   
minutes, and unlike MRI contrast agents, the microbubbles remain in intravascular 
compartment until excreted from the system. Two methods are available when using the 
contrast agent to assess tumor perfusion; power Doppler and dynamic contrast imaging: 
Use of power Doppler. When insonified by a high power ultrasound pulse, microbubbles 
disintegrate emitting a non-linear signal detectable with Doppler.  Power Doppler imaging 
using contrast agents and a high mechanical index allows detection of vessels down to 
capillary size and is independent of flow velocities [35]. Total vessel fraction within a tumor 
can thus be computed from a 3D sweep and the ratio of colorized pixels to the total number 
of pixels within the tumor can be calculated. 
Use of dynamic contrast imaging. The injection of a bolus of contrast can be monitored with 
low power (less than 0.1) mechanical index.  Simultaneous recording of the intensity 
changes of the contrast agent as a function of time will provide information on blood flow in 
a region of interest during the entire time of imaging. In brief, the uptake curve can be fitted 
to an exponential function using the formula y=A(1-e-t) where A is proportional to the 
microvascular cross-sectional area, and  corresponds to velocity [36]. The product of these 
two parameters can then be used to quantify perfusion. Additional parameters that have 
been used in tumor assessment include peak enhancement, area under the curve, and wash-
in-time [37]. The values obtained can be averaged across the tumor or evaluated on a pixel-
by-pixel case to create parametric maps that demonstrate tumor heterogeneity. 
The separation of fast flow (from larger functional vessels) and slow flow (from the 
microvasculature) can provide further insight to vasculature changes from treatment. In a 
study of an anti-angiogenic drug in a human/mouse chimera model, the quantification of 
CE-US imaging wash-in parameters revealed that the prevalence of fast blood flow, but not 
slow flow (associated with small, leaky vessels), was suppressed in treated tumors 
compared with control tumors [38]. 
4. Ultrasound imaging of tumor growth kinetics  
4.1 Changes in tumor volume and tumor composition 
In both the xenograft and orthotopic models B-mode imaging using high-frequency 
ultrasound can provide valuable data on the volume of the tumor.  Traditional tumor 
volume measurement in xenograft models uses caliper measurement of the tumor width 
www.intechopen.com
  Ultrasound Imaging – Medical Applications 290 
(W) and tumor length (L). An ellipsoid shape is assumed, and the volume computed as 
V=1/2 (L x W2). Using this technique, inter-observer variation is 15% [39]. Measurement of 
tumor volume using calipers is not possible in orthotopic animal models known to much 
closer resemble local and tumor vascular events seen in HCC patients relative to xenograft 
models [17]. Volume size estimates from a 3D ultrasound image set are more accurate due to 
the ability to account for non-ellipsoidal shapes. Currently, there are commercially available 
software that can view individual slices and manually outline the tumor on individual slices 
in both xenograft and orthotopic tumors in rats and mice. By interpolating between slices, 
an accurate representation of the 3D tumor shape is provided along with the volume 
estimation. For fine sweeps, not every slice needs to be evaluated.  We have found that with 
a slice separation in the range of 100 to 300 m, manual tumor delineation on every 10th slice 
provides accurate volume estimation (unpublished data).   
Along with tumor delineation, ultrasound grayscale images can also allow for detection of 
change in tumor composition including tumor necrosis.  Necrotic regions in tumor 
xenograft appear as fluid filled pockets within the tumor (Figure 6). By using the same 
techniques utilized to assess the tumor volume, the necrotic volume can also be estimated. 
 
 
Fig. 6. Example-scan of a xenograft tumor composed of human Huh7.5 cell line outlined in 
red with necrotic core outlined in yellow.   
4.2 Change of tumor vasculature following drug treatment 
Dynamic contrast methods may present some difficulties in the rodent liver due to 
breathing motion.  The high frequency ultrasound systems allow for respiratory gating, but 
the tumor bearing liver in rodents can still be difficult to image with sufficient accuracy. 
Early testing of anti-angiogenic compounds in both xenograft and orthotopic models have 
utilized US imaging in order to provide the proof of mechanism and facilitate design of 
follow-up clinical trials [40,41]. 
Ultrasound has been shown to help in quantifying changes in tumor perfusion in response to 
combination therapy [14]. In this study both, an anti-angiogenic mono-therapy and an anti-
angiogenic plus a tyrosine kinase inhibitor combination were tested. Under approval of the 
IACUC, male nude rats (Taconic) were implanted with Huh7.5 human hepatocarcinoma cells 
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suspended in Matrigel.  During the first phase of the study (days 5 - 21 after cell inoculation) 
rats were treated with either vehicle, sunitinib (Sutent®, Pfizer Inc.) or sunitinib plus a 
FAK/Pyk2 tyrosine kinase inhibitor (PF-562,271).  In the second phase of the study the rats 
switched treatments so that half of vehicle treated rats remained on vehicle,  the other half of 
vehicle treated rats switched to sunitinib + FAK/Pyk2 compound, rats receiving sunitinib 
alone switched to vehicle while rats receiving sunitinib + FAK/Pyk2 switched to vehicle. 
 
 
Fig. 7. Examples of parametric maps and uptake curves generated on HCC xenografts using 
contrast enhanced ultrasound imaging (CEUS). 
Using the high-frequency Vevo770 (VisualSonics, Toronto, ON), 3D grayscale volumes 
were collected along with B-scan cineloops of the center slice of the tumor.  These 
cineloops were collected at 50% power and 100 µl of contrast (MicroMarker, VisualSonics) 
was given as a slow bolus.  Ultrasound imaging, blood and tumor measurements by 
caliper were collected on day 10, 14, 21, and 28 post cell injection, under isoflurane 
anesthesia.  At the end of the study, day 36, the rats were euthanized and the livers were 
collected and processed for histology.  Ultrasound images were analyzed using in house 
developed methods based in Matlab (Mathworks).  Post processing involved both motion 
correction and filtering. 
Temporal uptake curves were obtained for each pixel, and pseudo-colored parametric maps 
were created to reflect spatial variation. Regions where the peak signal was less than a 
predefined threshold were labeled non-perfused. Region averages were then computed to 
provide data on total peak signal and peak signal without necrosis/non-perfused (Figure 8). 
Therefore, early testing of anti-angiogenic compounds for proof of mechanism using 
xenograft model provide valuable data that can be used to improve the design of the studies 
using orthotopic models as well as to devise a better plan human trials. Non-imaging 
assessment in the study published by Bagi et al. [13] showed there was a good correlation 
between results obtained by CEUS and tumor size measured by caliper as well as with 
serum alpha-fetoprotein levels (tumor cell biomarker). 
5. Summary  
Preclinical experimentation allows for simultaneous longitudinal implementation of 
imaging techniques along with use of serum biomarkers to monitor the growth and  
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Fig. 8. Representative images obtained by CEUS depicting HCC xenograft treated with 
vehicle (A) or sunitinib (B) at 2 different time-points. There is a clear difference in tumor size 
and vascularity between control and treated tumor. 
response to treatment of HCC tumors. Although, xenograft and orthotopic models are 
complementary, and both models have a place in the screening strategy of novel therapies 
based on the complex vascular events and microenvironment of the liver that plays a role in 
tumor growth and spreading, only orthotopic liver tumor models can provide the level of 
complexity that is needed to reliably evaluate the antitumor effects of compounds under 
investigation in preclinical studies.  
The first step to establish the clinical diagnosis of HCC in patients consists of a blood test for 
elevated AFP concentrations followed by structural imaging utilizing one of several imaging 
modalities that are currently available including ultrasonography. Ultrasonography has been 
validated for preclinical and clinical use and it has been one of the most valuable translational 
tools to assess the efficacy of novel therapies in animal models of HCC as well as in the 
patients. Additional technological advances toward developing safe contrast agents continue 
to add value to current ultrasonography methods. Therefore, the thorough preclinical research 
of HCC should include both, predictive animal models and reliable technologies. 
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